Chemomab Therapeutics Ltd.
CMMB
$1.74
-$0.03-1.70%
NASDAQ
| 12/31/2025 | 06/30/2025 | 12/31/2024 | 09/30/2024 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.85% | 16.07% | 6.79% | -11.72% | -16.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -38.56% | -39.97% | -16.50% | -15.04% | 70.09% |
| Operating Income | 38.56% | 39.97% | 16.50% | 15.04% | -70.09% |
| Income Before Tax | 36.79% | 43.35% | 13.29% | 15.79% | -71.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 36.79% | 43.35% | 13.29% | 14.65% | -71.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.79% | 43.35% | 13.29% | 14.65% | -71.49% |
| EBIT | 38.56% | 39.97% | 16.50% | 15.04% | -70.09% |
| EBITDA | 38.86% | 40.19% | 16.50% | 15.06% | -70.21% |
| EPS Basic | 61.89% | 65.04% | 40.16% | 42.45% | -77.01% |
| Normalized Basic EPS | 61.89% | 65.03% | 40.16% | -- | -76.58% |
| EPS Diluted | 61.89% | 65.04% | 40.16% | 42.45% | -77.01% |
| Normalized Diluted EPS | 61.89% | 65.03% | 40.16% | -- | -76.58% |
| Average Basic Shares Outstanding | 65.90% | 62.02% | 44.90% | 48.29% | -3.11% |
| Average Diluted Shares Outstanding | 65.87% | 61.97% | 45.07% | 48.24% | -3.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |